New genital herpes vaccine candidate provides powerful protection in preclinical tests

January 19, 2017
Herpes simplex virus. Credit: CDC

Approximately 500 million people around the world are infected with the genital herpes virus known as herpes simplex virus 2 (HSV2). A vaccine that could bring an end to this global pandemic is needed desperately, yet no candidate vaccine has ever performed well in clinical trials. Now scientists in the Perelman School of Medicine at the University of Pennsylvania have shown that a new type of vaccine provides powerful protection in standard guinea pig and monkey models of HSV2 infection.

The new "trivalent" vaccine induces antibodies against three different parts of the virus, including two components that normally help HSV2 evade .

"It's a novel strategy, and it works beautifully," said senior investigator Harvey M. Friedman, MD, a professor of Infectious Diseases at Penn. "I know of no other HSV2 with published results that are as promising as this study."

The findings, reported today in PLOS Pathogens, are likely to lead to human of the vaccine.

The public health burden from HSV2 is enormous. In the United States alone, researchers estimate that approximately one in six people age 15 to 49 have HSV2 infection. In some parts of Africa, more than half the adult population is thought to be infected. Aside from the direct burden on adults, HSV2 can cause devastating and often lethal infections of infants born to infected mothers. HSV2 infection also greatly increases the likelihood of HIV transmission and thus accounts for much of the HIV public health burden as well.

Candidate HSV2 vaccines developed in recent years have largely targeted gD2, a glycoprotein (a protein coated with sugar-like molecules) that is mounted on the virus's outer envelope and helps it break into host cells. However, vaccines targeting gD2 alone have not shown very robust protection in animal and human trials.

Friedman and his team, therefore, designed their new vaccine to induce an against not only gD2 but also two other viral glycoproteins, gC2 and gE2. The latter are known to block elements of the immune response, helping HSV2 to survive long-term in its hosts.

"In essence, we're stimulating the immune system to attack the virus and at the same time preventing the virus from using some of the tools it has to thwart that immune attack," Friedman said.

Working with the Tulane National Primate Center in Louisiana, Friedman and his group showed that the trivalent vaccine—given three times at monthly intervals—induced a strong immune response in macaque monkeys, whose immune system closely resembles the human version. The response included antibodies against gC2, gD2, and gE2 in both blood and vaginal secretions. In the lab dish, these antibodies potently neutralized HSV's ability to spread from cell to cell. The vaccine also induced a sharp rise in CD4 T-cells, whose job is to mobilize the antibody response and other immune elements against viral infections.

The researchers also showed that the antibodies induced by the trivalent vaccine potently neutralized four isolates of HSV2 from sub-Saharan Africa, where infection prevalence is very high.

Macaques do not usually develop genital lesions when infected with HSV2, but in this case, the unvaccinated monkeys showed signs of mild vaginal inflammation soon after exposure to the virus, whereas the vaccinated monkeys showed none.

In a second set of experiments, guinea pigs, which normally develop a more severe genital infection when infected with HSV2, were almost completely protected from genital lesions by the vaccine. The scientists were still able to detect a small amount of viral DNA in the genital secretions of the animals, but only a tiny fraction of this viral DNA was capable of replicating in cells.

"We are pleased to have demonstrated such a potent and durable immune response to the vaccine," said the study's lead author, Sita Awasthi, PhD, a research associate professor of Infectious Diseases at Penn. "If found effective in clinical trials, the vaccine will have a huge impact on reducing the overall prevalence of infections and could reduce new HIV infections as well, especially in high-burden regions of sub-Saharan Africa."

"If the vaccine behaves like this in people, it would limit lesions to appearing only about one day in 100, and the virus would be potentially contagious only about two in every 1,000 days," Friedman said.

In principle, he added, that would virtually shut down HSV2's ability to spread in the population.

Friedman and colleagues are now in discussions with pharmaceutical companies to move the vaccine, or an optimized version of it, into initial clinical trials.

If the does emerge successfully from clinical trials, it would probably be given on a schedule of three inoculations, at 0, 1 and 6 months.

Explore further: Preclinical evaluation of a vaccine against herpes viruses

Related Stories

Preclinical evaluation of a vaccine against herpes viruses

August 4, 2016
Oral and genital herpes are caused by the herpes simplex virus type 1 (HSV-1) and the herpes simplex virus type 2 (HSV-2), which both cause lifelong infection. HSV-2 infection is associated with increased risk for HIV infection. ...

Research advances potential for test and vaccine for genital and oral herpes

August 11, 2015
Findings from a pair of new studies could speed up the development of a universally accurate diagnostic test for human herpes simplex viruses (HSV), according to researchers at Johns Hopkins and Harvard universities and the ...

Engineered virus has artificial amino acid allowing it to serve as a vaccine

December 2, 2016
(Medical Xpress)—A team of researchers at Peking University has developed a new type of vaccine that they claim may allow for a new approach to generating live virus vaccines which could conceivably be adapted to any type ...

DNA-based vaccine guards against Zika in monkey study

September 22, 2016
An experimental DNA-based vaccine protected monkeys from infection with the birth defects-causing Zika virus, and it has proceeded to human safety trials, researchers report.

A novel therapy for genital herpes engages immune cells to provide significant patient benefits

June 20, 2016
A phase II clinical trial demonstrated that a new type of treatment for genital herpes, an immunotherapy called GEN-003, may reduce the activity of the virus and the number of days with recurrent herpes. This effect of treatment, ...

Researchers find alternative pathways to HIV antibodies

May 4, 2016
The immune system appears to hamper an investigational vaccine from inducing antibodies that protect against HIV infection, but there may be ways to overcome this impediment, according to research led by the Duke Human Vaccine ...

Recommended for you

New cellular approach found to control progression of chronic kidney disease

December 15, 2017
Researchers have demonstrated for the first time that extracellular vesicles - tiny protein-filled structures - isolated from amniotic fluid stem cells (AFSCs) can be used to effectively slow the progression of kidney damage ...

Testing shows differences in efficacy of Zika vaccines after one year

December 15, 2017
(Medical Xpress)—A large team of researchers with members from Harvard Medical School, Walter Reed Army Institute of Research, Bioqual Inc. and MIT has found that the efficacy of the three types of Zika vaccines currently ...

How to regulate fecal microbiota transplants

December 15, 2017
(Medical Xpress)—A small team of researchers at the University of Maryland, some with affiliations to the Veterans Affairs Maryland Health Care System, has written and published a Policy Forum piece in the journal Science ...

Screening could catch a quarter of hip fractures before they happen

December 15, 2017
Community screening for osteoporosis could prevent more than a quarter of hip fractures in older women - according to new research led by the University of East Anglia (UEA).

Urine test developed to test for tuberculosis

December 14, 2017
(Medical Xpress)—An international team of researchers has developed a urine test that can be used to detect tuberculosis (TB) in human patients. In their paper published in Science Translational Medicine, the group describes ...

40 years after first Ebola outbreak, survivors show signs they can stave off new infection

December 14, 2017
Survivors of the first known Ebola outbreak, which occurred in the Democratic Republic of the Congo in 1976, may be key to development of vaccines and therapeutic drugs to treat future outbreaks, according to a new study ...

3 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

regaska12
not rated yet Feb 26, 2017
Greetings to everybody, i want to inform the public how i was cured of HERPES Simplex Virus by Dr Bude after trying various medications which was very expensive to treat the symptoms and never cured me. I was browsing through the Internet searching for remedy on HERPES and i saw comment of people talking about how Dr Bude cured them of different diseases. I was scared because i never believed in the Internet but i was convince to give him a try because i was having no hope of been cured of HERPES so i decided to contact him on his email that was listed on the comment (drbudeherbalhome@gmail.com) i searched his email on net and i saw a lot of people testifying about his goodness. when i contacted him he gave me hope and sent a Herbal medicine to me that i took and it seriously worked for me, am a free person now without problem, my HERPES result came out negative. I will want everyone to know that Dr Bude is a great and powerful man and have super effective herbs that can also cure DIA
alfred57selina
not rated yet Mar 12, 2017


All thanks to Dr Oduku for the traditional herbal remedy he render to me,i
have been with HSV disease for so many yrs and i was at the point of death,
i came in contact with Dr Oduku and he prepare a herbal medicine for me and
send it to me through UPS delivery Service and i was using it prescribe,
today i am now totally free from the deadly disease with his herbal
medicine, if you are out there suffering from this terrible disease you can
also contact him odukuherbalremedies@gmail.com or you may call or whatsApp
him for directives via or WhatsApp +2349064430408 and also you can reach me
on +15204634748 all your health problem will be solve for a better
life.stay bless my friends. you can still search the Google to know more of
his products
sdalexsmithjr30
not rated yet Mar 14, 2017
I can't believe this. A great testimony that i must share to all herpes patient in the world. i never believed that their could be any complete cure for Herpes or any cure for herpes,i saw people's testimony on blog sites and Facebook page of how Dr olodumare prepare herbal cure and brought them back to life again. i had to try it too and you can,t believe that in just few weeks i started using it all my pains stop gradually and i had to leave without the herpes drugs the doctaor gave to me. Right now i can tell you that few months now i have not had any pain, and i have just went for test last week and the doctor confirmed that there is no trace of any herpes system on my body. contact Dr Olodumare via his email realherpestreatment1@gmail.com

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.